Status:
COMPLETED
Circulating Tumor Cell Detection in Hepatocellular Carcinoma
Lead Sponsor:
Tongji Hospital
Conditions:
Circulating Tumor Cell
Eligibility:
All Genders
18-80 years
Brief Summary
The investigators examined circulating tumor cells (CTC) in the perioperative peripheral blood of hundreds of HCC patients undergoing liver cancer surgery using CellSearch technology between 2013 and ...
Detailed Description
From 2013 to 2016, CellSearch technology was used to detect the number of circulating tumor cells (CTC) in peripheral blood of hundreds of HCC patients undergoing liver cancer surgery during periopera...
Eligibility Criteria
Inclusion
- The pathological diagnosis was primary liver cancer.
- Undergoing radical surgical treatment
- No preoperative antitumor therapy was received
- Between 18 and 80 years old
Exclusion
- With distal metastasis
- With other tumors
- Perioperative death
- Recurrence within one month after surgery
- Lost contact before the first follow-up
Key Trial Info
Start Date :
November 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 15 2022
Estimated Enrollment :
458 Patients enrolled
Trial Details
Trial ID
NCT05297955
Start Date
November 1 2013
End Date
March 15 2022
Last Update
April 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030